Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis

Abstract Objective To evaluate the efficacy and safety of galcanezumab in patients with migraine in a real-world setting in Japan. Background Galcanezumab is the first anti-calcitonin gene-related peptide monoclonal antibody approved in Japan. To the best of our knowledge, no real-world studies on g...

Full description

Bibliographic Details
Main Authors: Tsubasa Takizawa, Seiya Ohtani, Narumi Watanabe, Naoki Miyazaki, Kei Ishizuchi, Koji Sekiguchi, Chisato Iba, Mamoru Shibata, Ryo Takemura, Satoko Hori, Jin Nakahara
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Neurology
Subjects:
Galcanezumab
Migraine
Real-world evidence
Associated symptoms
Premonitory symptoms
Online Access:https://doi.org/10.1186/s12883-022-03041-1

Internet

https://doi.org/10.1186/s12883-022-03041-1

Similar Items